Browsing by Author "Anand Anunay"

Now showing 1 - 2 of 2

Engineered an ultrasmall curcumin oral nanoformulation restores intestinal integrity and gut microbiota dysbiosis
(Elsevier B.V., 2025) Vivek Sharma; Prateeksha Prateeksha; Balwant Singh Paliya; Sateesh Chandra Gupta; Sarvendra Singh; Anand Anunay; Sushil Agrahari; Shailendra P. Singh; Chandana Venketswara Rao; Saroj Kanta Barik; Brahma Nand Singh
Antibiotic therapy for bacterial infections often disrupts gut microbiota (GM) and intestinal integrity, inducing chronic inflammation and inflammatory bowel diseases. An effective therapeutic intervention is urgently needed to alleviate the aforementioned adverse effects of antibiotics. Curcumin (CUR) reveals great potential to restore intestinal integrity and GM dysbiosis due to its strong antiinflammatory and prebiotic effects. However, the weak solubility and stability of CUR result in limited bioavailability and a short half-life, which restricts its clinical uses. An ultra-small CUR oral nanoformulation was created using a carboxylated galactomannan (cGM), facilitated by hydrogen bonding between the phenolic hydroxyl groups of CUR and the carboxyl groups present on cGM. The developed nanoformulation increased CUR stability both in vitro and in vivo, extended its retention period in the gastrointestinal tract, and enhanced its permeability across the mucus layer and intestinal epithelium to improve oral bioavailability of CUR. The nanoformulation attained notable therapeutic efficacy in restoring intestinal epithelial barrier dysfunction and GM dysbiosis, as validated in an antibiotic-induced in vivo model. This research highlights the benefits of cGM in creating a very stable and ultrasmall nanoformulation for CUR, offering a promising oral nanoplatform for the delivery of CUR. © 2025
Transferosome-mediated delivery of epigallocatechin three gallate and curcumin: An advanced therapeutic strategy for management of pancreatic cancer and lymphoma model
(Elsevier Ltd, 2025) Virendra Pratap Singh; Gaurav Mishra; Gurvachan Singh; Anand Anunay; Divyanshi Singh; Biplob Koch; Anurag Kumar Tiwari
Background: Cancer remains a major global health issue, with lung cancer accounting for the highest mortality. Pancreatic cancer, more prevalent among men, has a 5-year survival rate of less than 5 %. Continued research into treatment options is crucial to combat pancreatic cancer. Methods: The present study aimed to investigate the potential effects of combination therapy with bioactive compounds epigallocatechin-3-gallate (EGCG) and curcumin (Cur) in pancreatic cancer and lymphoma models. The combination therapy (EGCG+Cur) was delivered via transferosomes (T). In vitro and in vivo studies were conducted to evaluate the effect of various combinations of EGCG and Cur in murine models of pancreatic cancer and T-cell lymphoma. Results: In vitro cytotoxicity assays showed that the combination therapy (EGCG+Cur-T) exhibited greater cytotoxicity than lone therapies (EGCG-T, Cur-T, crude EGCG and Cur). Microscopy, flow cytometry and Western blot studies revealed that EGCG+Cur-T (0.5 ± 0.12 µg/mL) effectively increased oxidative stress and promoted apoptosis. Analysis of cell cycle with combination therapy in RIN5 cells revealed effective G0–G1 arrest. EGCG+Cur-T showed greater efficacy than the positive control (cisplatin). Furthermore, in vivo studies reported that the EGCG+Cur-T treatment reduced tumour volume, restored liver architecture and extended murine survival compared with crude drug. Conclusion: This study investigated the potential of combination therapy (EGCG+Cur-T) for the treatment of pancreatic cancer in in vitro and in vivo models, highlighting the potential of transferosomes as a promising drug delivery system to improve cancer management. © 2025 Elsevier Ltd